Substituted 1-alkylamino-1-H-indazoles for the treatment of glaucoma

• US 7,439,262 B1
• Filed: 12/05/2007
• Issued: 10/21/2008
• Est. Priority Date: 12/15/2003
• Status: Expired due to Fees

• Current Assignee: Novartis Ag
• Original Assignee: Alcon Incorporated
• Inventors: May, Jesse A., Dantanarayana, Anura P.
• Primary Examiner(s): Saeed; Kamal A
• Application Number:
  US11/950,598
• Time in Patent Office: 321 Days
• Field of Search: 514/406, 548/361.1
• US Class Current: 514/406
• CPC Class Codes: A61K 31/416 condensed with carbocyclic ring systems, e.g. indazole
• CPC Class Codes: C07D 231/56 Benzopyrazoles; Hydrogenated benzopyrazoles

Abstract

Substituted 1-alkylamino-1H-indazoles for lowering intraocular pressure and treating glaucoma are disclosed.

Claims

1. A compound of Formula I:

2. The compound of claim 1, wherein for Formula I:

G=H or C_1-4 alkyl;

R¹,R²=H

R³=H; and

R⁴=C_1-4 alkyl.

3. The compound of claim 2, wherein for Formula I:

R=NR⁶R⁷ or OC_1-6alkyl optionally substituted with halogen or hydroxyl, wherein R⁶ and R⁷ are independently hydrogen or C_1-4alkyl.

4. The compound of claim 2 that is:

1-((S)-2-Aminopropyl)-1H-indazole-6-carboxylic acid ethyl ester and pharmaceutically acceptable salts thereof.

5. A topical ophthalmic composition comprising a pharmaceutically effective amount of a compound in an ophthalmically acceptable vehicle, wherein the compound is of Formula I:

6. The ophthalmic composition of claim 5, wherein for the compound of Formula I:

G=H or C_1-4 alkyl;

R¹,R²H

R³=H; and

R⁴=C_1-4 alkyl.

7. The ophthalmic composition of claim 6, wherein for the compound of Formula I:

R=NR⁶R⁷ or OC_1-6alkyl optionally substituted with halogen or hydroxyl,

wherein R⁶ and R⁷ are independently hydrogen or C_1-4alkyl.